1988年 以荣誉毕业生身份毕业于北京医学院；

　　1995年 获得Brandeis University大学分子生物学博士学位；

　　2002年 获得University of the State of New York医学博士学位。

　　2002年-2008年 Assistant Professor of Pathology and Laboratory Medicine, Weill Cornell Medical College

　　2008年-2013年 Associate Professor of Pathology and Laboratory Medicine, Weill Cornell Medical College

　　2013年-至今 Professor of Pathology, University of Chicago

　　1997年-1998年 Interim Assistant Director, Division of Molecular Diagnostics, Department of Pathology, University of Pittsburgh Medical Center

　　2002年-2013年 Director, Molecular Hematopathology Laboratory （CLIA-certified/CAP-accredited/NYScertified）， Department of Pathology and Laboratory Medicine, Weill Cornell Medical College

　　2013年至今 Division Director, Division of Genomic and Molecular Pathology, Dept. of Pathology, University of Chicago Medicine

　　审稿期刊：Blood， Leukemia, Cancer Cell，Haematologica，Journal of Molecular Diagnostics，Diagnostic Molecular Pathology，British Journal of Haematology，Archives of Pathology & Laboratory Medicine

　　临床兴趣：基因组学在临床病理/精准医学的应用及开发。

　　研究兴趣：B细胞受体信号通路生物及干预策略。

　　1. Guo A, Lu P, Coffey G, Conley P, Pandey A, Wang YL*. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. Oncotarget. 2017; 8（8）：12953-12967. PubMed [journal] PMID:28088788

　　2. Guo A, Lu P, Lee J, Zhen C, Chiosis G, Wang YL*. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. Oncogene. 2017; PubMed [journal] PMID: 28114285

　　3. Nabhan C, Raca G, Wang YL*. Prognosis in Chronic Lymphocytic Leukemia-Reply. JAMA oncology. 2015; 1（7）：988-9. PubMed [journal] PMID: 26448290

　　4. Nabhan C, Raca G, Wang YL*. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era. JAMA oncology. 2015; 1（7）：965-74. PubMed [journal] PMID:26181643

　　5. Zhang SQ, Smith SM, Zhang SY, Lynn Wang Y*. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. British journal of haematology. 2015; 170（4）：445-56. PubMed [journal] PMID: 25858358

　　6. Zhen C, Wang YL*. Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation. The Journal of molecular diagnostics :JMD. 2013; 15（5）：556-64. PubMed [journal] PMID: 23876601

　　7. Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T,Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G,Wang YL*, Cesarman E. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 2013; 122（16）：2837-47. PubMed [journal] PMID: 23943653, PMCID: PMC3798998

　　8. Gong JZ, Cook JR, Greiner TC, Hedvat C, Hill CE, Lim MS, Longtine JA, Sabath D,Wang YL*. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology. The Journal of molecular diagnostics : JMD. 2013;15（6）：733-44. PubMed [journal] PMID: 23978506

　　9. Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR,Wang YL*. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014; 28（3）：649-57. PubMed [journal] PMID: 24270740

　　10. Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, Racchumi J, Xu G, Wu H, Ma J,Steggerda SM, Coleman M, Leslie C, Wang YL*. Ibrutinib resistance in chronic lymphocytic leukemia. The New England journal of medicine. 2014; 370（24）：2352-4.NIHMSID: NIHMS702017 PubMed [journal] PMID: 24869597, PMCID: PMC4512173

　　11. Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, Coleman M, Wang YL*.Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.British journal of haematology. 2014; 166（6）：849-61. PubMed [journal] PMID:24957109

　　12. Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL*. Functional characterization of BTK（C481S） mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia. 2015; 29（4）：895-900. PubMed [journal] PMID: 25189416

　　13. Wang YL, Miao Q. To Live or to Die: Prosurvival Activity of PPARgamma in Cancers.PPAR research. 2008; 2008:209629. PubMed [journal] PMID: 18784849, PMCID:PMC2532487

　　14. Yang C, Lu P, Lee FY, Chadburn A, Barrientos JC, Leonard JP, Ye F, Zhang D,Knowles DM, Wang YL*. Tyrosine kinase inhibition in diffuse large B-cell lymphoma:molecular basis for antitumor activity and drug resistance of dasatinib.Leukemia. 2008; 22（9）：1755-66. PubMed [journal] PMID: 18596745

　　15. Song Z, Lu P, Furman RR, Leonard JP, Martin P, Tyrell L, Lee FY, Knowles DM,Coleman M, Wang YL*. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clinical cancer research :an official journal of the American Association for Cancer Research. 2010;16（2）：587-99. PubMed [journal] PMID: 20068106

　　16. Gomez M, Wu X, Wang YL*. Detection of BCL2-IGH using single-round PCR assays.Diagnostic molecular pathology : the American journal of surgical pathology, part B. 2005; 14（1）：17-22. PubMed [journal] PMID: 15714059

　　17. Lee JW, Chen Q, Knowles DM, Cesarman E, Wang YL*. beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia. The Journal of molecular diagnostics : JMD. 2006; 8（3）：385-9. PubMed [journal] PMID: 16825513, PMCID: PMC1867607

　　18. Jo SH, Yang C, Miao Q, Marzec M, Wasik MA, Lu P, Wang YL*. Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities. Journal of immunology （Baltimore, Md. :1950）。 2006; 177（6）：3737-45. PubMed [journal] PMID: 16951334

　　19. Yang C, Jo SH, Csernus B, Hyjek E, Liu Y, Chadburn A, Wang YL*. Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism. The American journal of pathology. 2007; 170（2）：722-32. PubMed [journal] PMID: 17255338, PMCID:PMC1851856

　　20. Chen Q, Lu P, Jones AV, Cross NC, Silver RT, Wang YL*. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay,for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.The Journal of molecular diagnostics : JMD. 2007; 9（2）：272-6. PubMed [journal] PMID: 17384221, PMCID: PMC1867436